$11.6 billion! Pfizer completed its acquisition of Biohaven, a biopharmaceutical company, on October 3

發(fā)布時間： 2022-09-30 閱讀：354次

分享

Pfizer (PFE.US) 's $11.6 billion acquisition of Biohaven (BHVN.US) will be completed on October 3, according to the Securities and Exchange Commission.

Pfizer announced plans to acquire Biohaven in May. After the acquisition, Pfizer will receive zavegepant, a phase 3 migraine candidate, as well as other late-stage assets for the treatment of diseases such as obsessive-compulsive disorder, amyotrophic lateral sclerosis, and spinal muscular atrophy.
Biohaven 's migraine drug NurtecODT (rimegepant) had net revenue of $123.6 million in the first quarter of 2022.

In May, Pfizer announced plans to acquire Biohaven for $11.6 billion, at a 78.6% premium, one of the world 's largest pharmaceutical mergers in 2022.